FDA to review Medtronics Endeavor drug-eluting stent
Medtronic announced that a U.S. Food and Drug Administration’s (FDA) advisory panel will review the premarket approval (PMA) application for its Endeavor Drug Eluting Coronary Stent in October this year. The FDA will release the exact date four to six weeks prior to the meeting.

According to the Minneapolis-based company, its PMA application included safety and efficacy data on more than 4,100 patients, who have been treated in clinical trials with the Endeavor stent and monitored for up to four years.